Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
2026.01.25
Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
2026.01.24
Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
2026.01.23
Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
2026.01.23
2025 Tianjin International Breast Cancer Conference | Prof. Jihui Hao: A Blueprint for Intelligent Breast Cancer Prevention and Care
2026.01.20
2025 Tianjin International Breast Cancer Conference | Prof. Zhongsheng Tong: Targeted Therapy Frontiers and the “Tianjin Experience”
2026.01.20
2025 Yat-sen Breast Cancer Conference | Prof. Qiang Liu: Advancing Multidisciplinary Care for Breast Cancer in China
2026.01.20
2025 Yat-sen Breast Cancer Conference丨Professor Jing Yao: Addressing the Multiple Unique Needs of Young Breast Cancer Patients and Optimizing Treatment Choices Through Patient-Centered Care
2026.01.20
SABCS 2025 Insight Broadcast丨Professor Junjie Li: Exploring Precision Biomarkers for Neoadjuvant Therapy in HER2-Positive Breast Cancer
2026.01.20
SABCS 2025 Insight Broadcast: Professor Jin Yang: Interpreting the New Landscape of First-Line Advanced and Early Adjuvant Therapy for HR+/HER2− Breast Cancer
2026.01.20
Posted inUroStream

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Posted by By Mourabit Halima 2026.01.25
Continue Reading
Posted inIOncology

Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance

Posted by By Mourabit Halima 2026.01.24
Continue Reading
ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

Posted by By Mourabit Halima 2025.12.17
On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…
Read More
ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

Posted by By Peng Longmei 2025.12.17
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…
Read More
ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

Posted by By Mourabit Halima 2025.12.17
At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…
Read More
ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

Posted by By Peter W. PENG 2025.12.16
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together the latest global research and clinical advances…
Read More
ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

Posted by By Peng Longmei 2025.12.16
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international congress…
Read More
ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

Posted by By Mourabit Halima 2025.12.16
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by marked heterogeneity and complex prognosis. While treatment of intermediate- and high-risk disease remains challenging, there is also considerable…
Read More
ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

ICIC 2025丨Xiaowen Tang, MD, PhD: VA Plus Modified BuCy Conditioning Advances Transplant Outcomes in High-Risk ALL

Posted by By Mourabit Halima 2025.12.15
To promote innovation in China’s cell and immunotherapy fields, deepen scientific exchange, and accelerate translation through global collaboration, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held on…
Read More
TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

TROPION-Breast02 Insights: Redefining First-Line Therapy for Advanced Triple-Negative Breast Cancer

Posted by By Mourabit Halima 2025.12.15
At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…
Read More
Professor Yige Bao: Perioperative Vidicitamab Plus Immunotherapy Enables Kidney-Sparing Treatment in High-Risk UTUC

Professor Yige Bao: Perioperative Vidicitamab Plus Immunotherapy Enables Kidney-Sparing Treatment in High-Risk UTUC

Posted by By Peng Longmei 2025.12.14
Editor’s note: Upper tract urothelial carcinoma (UTUC) accounts for about 17.9% of all urothelial carcinomas (UC) in China. For high-risk UTUC, radical nephroureterectomy (RNU) is the standard surgical procedure, but…
Read More
NCCU 2025丨Prof. Shan Zheng: Piercing Through the Pink — How to Overcome Diagnostic and Prognostic Challenges in Eosinophilic Renal Tumors?

NCCU 2025丨Prof. Shan Zheng: Piercing Through the Pink — How to Overcome Diagnostic and Prognostic Challenges in Eosinophilic Renal Tumors?

Posted by By Mourabit Halima 2025.12.14
Editor’s note: The incidence of genitourinary cancers in China has continued to rise, with prostate, bladder, and kidney cancers ranking among the most common malignancies. Among them, eosinophilic renal tumors…
Read More

Posts pagination

Previous page 1 … 12 13 14 15 16 … 20 Next page
Recent Posts
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
  • Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
  • Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
  • 2025 Tianjin International Breast Cancer Conference | Prof. Jihui Hao: A Blueprint for Intelligent Breast Cancer Prevention and Care
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inUroStream
    Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
    Posted by By Mourabit Halima 2026.01.25
    Posted inIOncology
    Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
    Posted by By Mourabit Halima 2026.01.24
    Posted inUroStream
    Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
    Posted by By Mourabit Halima 2026.01.23
    Posted inUroStream
    Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
    Posted by By Mourabit Halima 2026.01.23
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied